bioAffinity Misses Q2 Revenue Target

bioAffinity Technologies (NASDAQ:BIAF), a biotechnology company focused on noninvasive diagnostics and cancer therapeutics, reported results for Q2 2025 on August 14, 2025. The most significant news from the release was that GAAP revenue came in well below analyst expectations, and GAAP EPS showed a wider loss than forecast. Net revenue was $1.27 million, short of the $1.51 million estimate and down from $2.4 million (GAAP) in Q2 2024. GAAP EPS was a loss of $(0.17), falling below the GAAP consensus of $(0.10) and slightly improved from $(0.19) per share (GAAP) in Q2 2024. The company highlighted cost-cutting progress and accelerating adoption of its main diagnostic test. However, overall financial performance remained pressured, and cash reserves declined further, making future liquidity a key concern.

Source: Analyst estimates for the quarter provided by FactSet.

bioAffinity Technologies develops diagnostic tests and new drug therapies mostly aimed at lung cancer. Its main commercial product, CyPath® Lung, is a laboratory-developed test designed to detect lung cancer at an early stage using a noninvasive sputum sample.

Continue reading

Source Fool.com